Few centres in the world can integrate laboratory science and AI under one roof
For decades, myalgic encephalomyelitis and chronic fatigue syndrome has occupied a troubling silence in medicine — affecting tens of millions yet yielding no diagnostic test, no biomarker, no clear biological explanation. Now, Western University has joined a €7.5 million European consortium called DISCOVER-ME, becoming the only North American institution invited into an international effort to finally illuminate the biological roots of this debilitating illness. Drawing on artificial intelligence, proteomics, and metabolomics, researchers in London, Ontario will analyze blood samples from hundreds of patients across Europe, searching for the molecular signatures that have long eluded science. It is a moment that reflects not only a scientific ambition, but a long-overdue reckoning with how seriously this disease deserves to be taken.
- Millions of people worldwide remain trapped in a condition that medicine cannot yet diagnose, measure, or treat — a profound failure that DISCOVER-ME is now racing to correct.
- The cruelest dimension of ME/CFS is post-exertional malaise, where even minor effort can send a patient into days or weeks of collapse, making the absence of answers not just frustrating but functionally devastating.
- Western University's inclusion as the sole non-European partner signals a deliberate strategic choice: its rare combination of laboratory science, computational biology, and clinical expertise makes it uniquely capable of handling the consortium's most complex analytical work.
- Data from over 700 patients will flow into Western's labs, where proteomics, metabolomics, and machine learning will be deployed together to hunt for the biological patterns that distinguish ME/CFS from healthy baselines.
- The project carries the momentum of precedent — Western's lead researchers previously built the world's largest precision medicine trial for long COVID, giving DISCOVER-ME both a proven framework and a credible path toward transforming ME/CFS from mystery to mechanism.
Western University has claimed a singular place in one of Europe's most ambitious medical research efforts — the only North American institution invited into DISCOVER-ME, a consortium backed by €7.5 million from the EU's Horizon Europe program and dedicated to finally understanding myalgic encephalomyelitis and chronic fatigue syndrome.
ME/CFS is one of medicine's most stubborn unsolved problems. Somewhere between 17 and 24 million people live with it globally, though the true number is likely higher. The illness disrupts the immune, nervous, and endocrine systems simultaneously, and its defining cruelty is post-exertional malaise — a phenomenon where even modest exertion can trigger a severe, delayed collapse in symptoms. Despite this, no validated diagnostic test exists. No biomarker. No objective window into what is actually happening inside patients' bodies.
Western's role is to serve as the consortium's analytical engine. Dr. Douglas Fraser, who holds the GSK Chair in Clinical Pharmacology at Schulich School of Medicine & Dentistry, and Mark Daley, the university's chief AI officer, will lead the work. Blood samples collected from patients across Europe will travel to London, Ontario, where they will be subjected to proteomics and metabolomics analysis — molecular techniques capable of mapping proteins and metabolites at extraordinary resolution. Machine learning will then search the resulting data for the biological signatures that set ME/CFS patients apart.
The broader consortium includes MedUni Vienna, Imperial College London, the Quadram Institute Bioscience, and France's CNRS. Together, they will analyze data from more than 700 ME/CFS patients and nearly 200 controls, alongside thousands of detailed clinical records — a scale designed to move science from description toward mechanism.
Fraser's credentials lend the effort particular credibility. He previously directed the world's largest precision medicine clinical trial for long COVID, and his experience studying post-viral disease gives DISCOVER-ME both a tested framework and a researcher who understands the terrain. Daley brings the computational depth needed to extract meaning from vast biological datasets.
What the invitation itself signals may matter as much as the science. For decades, ME/CFS was minimized or dismissed — sometimes treated as psychological rather than biological. Building a major research hub outside Europe specifically to handle this work reflects a genuine shift in how the medical establishment now regards the disease. If DISCOVER-ME succeeds, it could establish the biological foundation for targeted treatments where none currently exist — not an incremental advance, but a transformation for millions who have waited far too long.
Western University has secured a singular position in one of Europe's most ambitious medical research initiatives—the only North American institution invited to join a consortium investigating myalgic encephalomyelitis and chronic fatigue syndrome, the debilitating illness commonly known as ME/CFS. The project, called DISCOVER-ME and backed by the European Union's Horizon Europe program with €7.5 million in funding, represents a coordinated international effort to finally understand what causes the disease and how to treat it effectively.
ME/CFS remains one of medicine's stubborn mysteries. Between 17 and 24 million people worldwide live with the condition, though researchers suspect the actual number is far higher. The illness attacks multiple systems at once—the immune system, the nervous system, the endocrine system—and fundamentally disrupts the body's ability to generate and regulate energy. The cruelest feature is post-exertional malaise, a phenomenon in which even modest physical or mental exertion can trigger a severe and often delayed crash in symptoms. A person might feel manageable one day, push themselves slightly, and spend the next week bedridden. Yet despite affecting millions and causing profound disability, ME/CFS has no validated laboratory test, no biomarker, no objective way to diagnose it. Doctors remain largely in the dark about what actually happens inside the bodies of people who have it.
Western's role in DISCOVER-ME centers on its capacity to do something few institutions in the world can do simultaneously: combine cutting-edge laboratory science, computational biology, and clinical expertise under a single roof. Dr. Douglas Fraser, who holds the GSK Chair in Clinical Pharmacology at Western's Schulich School of Medicine & Dentistry, and Mark Daley, the university's chief AI officer, will lead the analytical work. Blood samples collected from patients across Europe will be shipped to London, Ontario, where Fraser's and Daley's teams will subject them to sophisticated molecular analysis—proteomics and metabolomics techniques that map proteins and metabolites at extraordinary resolution. Machine learning and artificial intelligence will then sift through the patterns, looking for the biological signatures that distinguish ME/CFS patients from healthy controls.
The consortium itself brings together some of Europe's leading research institutions: MedUni Vienna, which is leading the effort; Imperial College London; the Quadram Institute Bioscience; and France's Centre national de la recherche scientifique. The project will collect and analyze clinical and biological data from more than 700 ME/CFS patients and nearly 200 control participants, alongside 2,000 detailed clinical datasets. That scale of data, combined with Western's analytical firepower, creates an unprecedented opportunity to move beyond description toward mechanism—to answer not just what ME/CFS looks like, but why it happens.
Fraser brings formidable credentials to the work. He is a world-recognized expert in precision medicine and treatment optimization, having previously led investigations into long COVID, severe traumatic brain injury, and pediatric sepsis. His experience directing the world's largest precision medicine clinical trial for long COVID gives him both a proven framework and a track record of success in studying post-viral disease. Daley, as an international leader in natural computing, computational neuroscience, and bioinformatics, brings the computational sophistication needed to extract meaning from vast biological datasets.
What makes Western's invitation particularly significant is what it signals about the state of ME/CFS research. For decades, the illness was dismissed or minimized, sometimes even treated as psychological rather than biological. The decision to include Western—to build a major international research hub outside Europe specifically to handle the analytical work—reflects a fundamental shift in how the medical establishment now views the disease. It is being treated as a serious, urgent, biological problem worthy of major investment and international collaboration.
Fraser has framed the opportunity in terms of transformation. The framework that worked for long COVID—bringing researchers from around the world together toward a common goal—can now be applied to ME/CFS. If successful, DISCOVER-ME could establish the biological foundation for targeted, effective treatments where none currently exist. For the millions living with the disease, the potential is not incremental. It is the difference between a condition that remains mysterious and one that can finally be diagnosed, understood, and treated.
Notable Quotes
Being invited to join this international consortium is an incredible opportunity for Western to help uncover the biological causes of ME/CFS and accelerate the development of new, more effective treatments.— Dr. Douglas Fraser, GSK Chair in Clinical Pharmacology at Western's Schulich School of Medicine & Dentistry
By bringing that proven framework to ME/CFS, we have an opportunity to transform our understanding of the disease and move much closer to targeted, effective treatments.— Dr. Douglas Fraser, referencing Western's experience leading the world's largest precision medicine clinical trial for long COVID
The Hearth Conversation Another angle on the story
Why is Western the only North American institution in this consortium? What do they have that others don't?
It comes down to a specific combination of capabilities. You need laboratory scientists who can run sophisticated molecular analysis, computer scientists who can make sense of massive biological datasets, and clinicians who understand the disease. Most institutions have one or two of those. Western has all three in the same place, working together. That's rare enough that it made them essential to the project.
The article mentions that ME/CFS has no validated diagnostic test. How does that shape what this research is trying to do?
It's the whole problem. Right now, doctors diagnose ME/CFS by ruling out everything else—it's a diagnosis of exclusion. If you can find biological markers, biomarkers that show up in blood or other samples, you can actually diagnose it. That's what this project is hunting for. They're analyzing blood from over 700 patients looking for patterns that distinguish them from healthy people.
Post-exertional malaise sounds like the defining feature. Is that what they're trying to understand first?
It's certainly what makes the disease so disabling. But understanding post-exertional malaise means understanding the whole system—how the immune system, the nervous system, and the energy-producing machinery in cells all interact. That's why they're looking at immune function, metabolism, hormonal regulation, and mitochondrial activity all together. You can't isolate one piece.
Fraser led the world's largest precision medicine trial for long COVID. Is this project essentially applying that same approach to ME/CFS?
Exactly. He's taking a proven framework—international collaboration, precision medicine methodology, large-scale data collection—and applying it to a disease that's been neglected for much longer. Long COVID is only a few years old as a recognized condition. ME/CFS has been around for decades with far less research investment. This is a chance to finally give it the same level of scientific attention.
What changes if they succeed? What does a validated diagnostic test actually mean for patients?
It means you stop being gaslit. Right now, patients often spend years being told it's in their head, or that they need to exercise more—which actually makes them worse. A real diagnostic test means doctors can say: this is real, this is measurable, this is biological. From there, you can develop actual treatments instead of just managing symptoms.